Lv11
40 积分 2025-12-02 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
21小时前
已完结
皖公网安备34019202002308
